| Symbol | TRVI |
|---|---|
| Name | TREVI THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 195 CHURCH STREET,16TH FLOOR, NEW HAVEN, Connecticut, 06510, United States |
| Telephone | +1 203 304-2499 |
| Fax | — |
| — | |
| Website | https://www.trevitherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001563880 |
| Description | Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinsons disease. Additional info from NASDAQ: |
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
Read moreTrevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Read moreMathers Edward T 🟢 acquired 35.0K shares (1 derivative) of Trevi Therapeutics, Inc. (TRVI) at $13.45 Transaction Date: Jun 03, 2026 | Filing ID: 257488
Read more(99% Neutral) TREVI THERAPEUTICS, INC. (TRVI) Announces Executive Changes
Read moreColangelo Dominick 🟢 acquired 35.0K shares (1 derivative) of Trevi Therapeutics, Inc. (TRVI) at $13.45 Transaction Date: Jun 03, 2026 | Filing ID: 257370
Read moreMeeker David P 🟢 acquired 35.0K shares (1 derivative) of Trevi Therapeutics, Inc. (TRVI) at $13.45 Transaction Date: Jun 03, 2026 | Filing ID: 257373
Read moreVANLENT ANNE 🟢 acquired 35.0K shares (1 derivative) of Trevi Therapeutics, Inc. (TRVI) at $13.45 Transaction Date: Jun 03, 2026 | Filing ID: 257371
Read moreNew Form SCHEDULE 13D/A - Trevi Therapeutics, Inc. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001072613-26-000382 <b>Size:</b> 104 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07671911 | Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbup… | Phase3 | Idiopathic Pulmonary Fibrosis | Recruiting | 2026-06-29 | 2028-07-01 | ClinicalTrials.gov |
| NCT07671924 | The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants Wit… | Phase2 | Refractory Chronic Cough | Recruiting | 2026-06-22 | 2027-09-01 | ClinicalTrials.gov |
| NCT07487740 | A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Exte… | Phase1 | Healthy Participants | Completed | 2026-02-27 | 2026-05-19 | ClinicalTrials.gov |
| NCT07036029 | NAL ER IPF Respiratory Function and Safety Study | Phase1 | Idiopathic Pulmonary Fibrosis | Completed | 2025-08-21 | 2026-06-30 | ClinicalTrials.gov |
| NCT07015398 | A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and… | Phase1 | Healthy Participants | Completed | 2025-06-30 | 2025-09-26 | ClinicalTrials.gov |
| NCT05964335 | Cough Reduction in IPF With Nalbuphine ER | Phase2 | Idiopathic Pulmonary Fibrosis | Completed | 2024-02-06 | 2025-04-24 | ClinicalTrials.gov |
| NCT05962151 | Refractory Chronic Cough Improvement Via NAL ER (RIVER) | Phase2 | Refractory Chronic Cough | Completed | 2023-11-30 | 2025-01-06 | ClinicalTrials.gov |
| NCT04030026 | A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (I… | Phase2 | Idiopathic Pulmonary Fibrosis | Completed | 2019-10-29 | 2022-05-27 | ClinicalTrials.gov |
| NCT04020016 | Study of Nalbuphine ER in Participants With Hepatic Impairment | Phase1 | Hepatic Impairment | Completed | 2019-06-12 | 2020-02-05 | ClinicalTrials.gov |
| NCT03497975 | PRISM Study-Pruritus Relief Through Itch Scratch Modulation | Phase2 | Prurigo Nodularis | Completed | 2018-08-07 | 2023-02-24 | ClinicalTrials.gov |
| NCT04018664 | Oral Abuse Potential Study of Nalbuphine | Phase1 | Nalbuphine | Completed | 2018-05-29 | 2020-06-02 | ClinicalTrials.gov |
| NCT02174432 | Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodula… | Phase2 | Prurigo Nodularis | Completed | 2015-08-15 | 2017-09-03 | ClinicalTrials.gov |
| NCT02174419 | Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis | Phase2 | Prurigo Nodularis | Completed | 2015-03-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02143973 | Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With U… | Phase2 | Uremic Pruritus | Completed | 2014-09-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02143648 | Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus | Phase2 | Uremic Pruritus | Completed | 2014-06-01 | 2015-07-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Idiopathic Pulmonary Fibrosis | RECRUITING | NCT07671911 |
| NAL ER | Other | Phase PHASE3 | Idiopathic Pulmonary Fibrosis | RECRUITING | NCT07671911 |
| NAL ER | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT07487740 |
| Placebo | Other | Phase PHASE2 | Refractory Chronic Cough | RECRUITING | NCT07671924 |
| NAL ER | Other | Phase PHASE2 | Refractory Chronic Cough | RECRUITING | NCT07671924 |
| Placebo | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT07036029 |
| NAL ER | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT07036029 |
| Placebo | Other | Phase PHASE2 | Refractory Chronic Cough | RECRUITING | NCT07671924 |
| NAL ER | Other | Phase PHASE2 | Refractory Chronic Cough | RECRUITING | NCT07671924 |
| Placebo | Other | Phase PHASE3 | Idiopathic Pulmonary Fibrosis | RECRUITING | NCT07671911 |
| NAL ER | Other | Phase PHASE3 | Idiopathic Pulmonary Fibrosis | RECRUITING | NCT07671911 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT05964335 |
| NAL ER | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT05964335 |
| Placebo | Other | Phase PHASE2 | Refractory Chronic Cough | NOT_YET_RECRUITING | NCT07671924 |
| NAL ER | Other | Phase PHASE2 | Refractory Chronic Cough | NOT_YET_RECRUITING | NCT07671924 |
| Placebo | Other | Phase PHASE3 | Idiopathic Pulmonary Fibrosis | NOT_YET_RECRUITING | NCT07671911 |
| NAL ER | Other | Phase PHASE3 | Idiopathic Pulmonary Fibrosis | NOT_YET_RECRUITING | NCT07671911 |
| Placebo solution | Other | Phase PHASE1 | Nalbuphine | COMPLETED | NCT04018664 |
| Nalbuphine HCl solution | Other | Phase PHASE1 | Nalbuphine | COMPLETED | NCT04018664 |
| nalbuphine HCl ER | Other | Phase PHASE2 | Prurigo Nodularis | COMPLETED | NCT02174432 |
| Placebo tablets BID | Other | Phase PHASE2 | Prurigo Nodularis | COMPLETED | NCT02174419 |
| nalbuphine HCl ER tablets 180 mg BID | Other | Phase PHASE2 | Prurigo Nodularis | COMPLETED | NCT02174419 |
| nalbuphine HCl ER tablets 90 mg BID | Other | Phase PHASE2 | Prurigo Nodularis | COMPLETED | NCT02174419 |
| nalbuphine HCl ER | Other | Phase PHASE2 | Uremic Pruritus | COMPLETED | NCT02143973 |
| Placebo tablets BID | Other | Phase PHASE2 | Uremic Pruritus | COMPLETED | NCT02143648 |
| nalbuphine HCl ER tablets 120mg BID | Other | Phase PHASE2 | Uremic Pruritus | COMPLETED | NCT02143648 |
| nalbuphine HCl ER tablets 60 mg BID | Other | Phase PHASE2 | Uremic Pruritus | COMPLETED | NCT02143648 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT04030026 |
| NAL ER | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT04030026 |
| Placebo Tablets | Other | Phase PHASE2 | Prurigo Nodularis | COMPLETED | NCT03497975 |
| Nalbuphine ER Tablets | Other | Phase PHASE2 | Prurigo Nodularis | COMPLETED | NCT03497975 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT05964335 |
| NAL ER | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT05964335 |
| Nintedanib | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT07015398 |
| Pirfenidone | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT07015398 |
| NAL ER | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT07015398 |
| Placebo | Other | Phase PHASE2 | Refractory Chronic Cough | COMPLETED | NCT05962151 |
| NAL ER | Other | Phase PHASE2 | Refractory Chronic Cough | COMPLETED | NCT05962151 |
| Nalbuphine ER | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT04020016 |
| NAL ER | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07487740 |
| Placebo | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | RECRUITING | NCT07036029 |
| NAL ER | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | RECRUITING | NCT07036029 |